Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 2.0 Contact Hours.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient Outcomes

Release Date: August 31, 2017
Expiration Date: August 31, 2018
Media: Internet - based

 

Activity Overview

Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient Outcomes is a continuing medical education (CME)-certified activity based on a symposium of the same name held in Chicago, Illinois, on June 4, 2017.

The management of advanced forms of lung cancer has been transformed in recent years because of remarkable developments in molecular diagnostics and new therapies. The targeting of known oncogenic drivers has allowed for the development of strategies that aim to improve efficacy and minimize toxicity compared with previous standards of care. Indeed, personalized care is now the standard of care in non–small cell lung cancer (NSCLC). Tyrosine kinase inhibitors (TKIs) have brought hope to patients with several types of cancer in multiple lines of therapy, including epidermal growth factor receptor (EGFR)-mutated and anaplastic lymphoma kinase (ALK)-translocated NSCLC. In patient populations that have received targeted treatments, impressive clinical benefit has been achieved with TKIs that target mutated EGFR or ALK. These changes are welcome, and the field continues to move forward, with new diagnostic techniques and an ever-expanding array of therapeutic options in the different lines of therapy. The continual advances in the treatment of patients with oncogenic driver–mutated NSCLC create practice and educational gaps for clinical oncologists who strive to maintain state-of-the-art care for their patients. To meet this educational need, this interactive live symposium has assembled internationally recognized experts in lung cancer research and care to provide cutting-edge approaches that can be applied immediately to clinical practice.

This CME activity consists of a series of brief interviews with 3 internationally recognized experts in lung cancer research and care exploring clinically relevant questions concerning the use of oncogenic-driven treatment from the community physician perspective. We invite you to join these experts as they guide participants through the rapidly evolving treatment landscape. Important topics addressed in this activity include:

  • The landscape of actionable oncogenic drivers in lung cancer in 2017
  • Choosing therapy for patients with EGFR-mutated NSCLC
  • Assessing and responding to acquired resistance
  • Therapeutic options for patients with ALK- and ROS1-rearranged lung cancer

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

CME/CE Activity Table of Contents

  • Module 1: A Patient With EGFR-Mutated NSCLC
  • Module 2: A Patient With ALK-Rearranged NSCLC

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a cme/ce certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a cme/ce certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists who treat patients with lung cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of cancer may also participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Apply clinical trial evidence for decision making to personalize care in the frontline setting of NSCLC with actionable mutations
  • Outline multidisciplinary methods to facilitate tumor tissue characterization, rebiopsy, or liquid biopsies to identify actionable mutations in multiple lines of care for patients with lung cancer
  • Assess current and emerging strategies to address the problem of acquired resistance and relapse in patients with NSCLC
  • Personalize care via the use of tumor- and patient-specific characteristics for patients with advanced forms of NSCLC beyond disease progression

Faculty, Staff, and Planners' Disclosures

Chair

David R. Gandara, MD
Professor of Medicine
Division of Hematology/Oncology
Director, Thoracic Oncology Program
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Sacramento, CA

Disclosure: Grant/Research Support: Genentech, Novartis, AstraZeneca; Consultant: Genentech, Novartis, AstraZeneca.

Faculty

Fred R. Hirsch, MD, PhD
Professor of Medicine and Pathology
Division of Medical Oncology
University of Colorado Denver School of Medicine
Associate Director for International Programs
University of Colorado Cancer Center
Aurora, CO

Disclosure: Grant Research Support: Bayer, Bristol-Myers Squibb; Consultant: Lilly, Genentech/Roche, Bristol-Myers Squibb, AstraZeneca.

Geoffrey R. Oxnard, MD
Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA
 

Disclosure: Conulstant: Ariad, AstraZeneca, Inivota, Novartis, Chugai Pharma, Bio-Rad Laboratories, Sysmex.

Heather A. Wakelee, MD
Associate Professor of Medicine (Oncology)
Stanford University Medical Center
Stanford, CA
 
 

Disclosure: Grant Research Support: Clovis Oncology, Exelixis, AstraZeneca/MedImmune, Genentech/Roche, Bristol-Myers Squibb, Gilead, Novartis, Xcovery, Pfizer, Celgene, Pharmacyclics, Lilly; Consultant: Peregrine, ACEA Biosciences, Pfizer, Helsinn Therapeutics, Genentech (uncompensated).

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

CME/CE Provider Contact Information

Physicians’ Education Resource®, LLC
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
info@gotoper.com

Hardware And Software Requirements 

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)

  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Minimum System Requirements (Mac OS)

  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise






Become a Member

Forgot Password?
Filter By